B Cell Repertoire in Determining Responses to Checkpoint Blockade in NSCLC
31 Jan 2023
Immune-related adverse events following checkpoint blockade are the achilles heel of this revolutionary treatment paradigm in cancer. This poses not only a significant healthcare burden in terms of increased morbidity and mortality to our patients, but also a huge financial and socioeconomic burden. Elucidating the mechanisms underpinning this phenomenon is of key importance to be able to stratify patients at risk of toxicity and improve long-term treatment outcomes.
Key learning objectives
- Discover the mechanisms of immunotherapy
- Understand the burden and incidence of immune-related adverse events
- Review biological mechanisms
- Explore biomarker research
Who should attend?
- Researchers, post-docs, scientists, and professors in academia and pharmaceuticals working in the fields of biomarker discovery
- Those working in patient stratification, therapeutic response prediction and diagnostics, and CDx development for immuno-oncology, autoimmune and neurological diseases
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.